NSE: VIJAYA | BSE: 543350

Expensive Performer

Download real time

965.40 -5.55 (-0.57%)

High vol. this week

NSE 11 Apr, 2025 3:31 PM (IST)

9,908.5

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Vijaya Diagnostic Centre Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for VIJAYA, BSE:543350 Vijaya Diagnostic Centre Ltd.

Search Inside the pdf :

Vijaya Diagnostic Centre Ltd.

07 Apr 2025

965.40

-0.57%

VIJAYA DIAGNOSTIC CEN LTD

Buy: Vijaya Diagnostic Centre Ltd.

FundsIndia

FundsIndia released a Buy report for Vijaya Diagnostic Centre Ltd. with a price target of 1067.0 on 07 Apr, 2025.

Vijaya Diagnostic Centre Ltd.

07 Aug 2024

965.40

-0.57%

PH relieves pain in margin of base business

Hold: Vijaya Diagnostic Centre Ltd.

Recommendation Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q1FY25 performance was ahead of our expectations. Base business grew at 19.6%driven by 16.6% YoY rise in patient footfall and 19.8% YoY jump in number of tests while EBITDA grew 17% YoY.

Number of FII/FPI investors increased from 138 to 155 in Dec 2024 qtr.

Vijaya Diagnostic Centre Ltd.

08 Nov 2023

965.40

-0.57%

Striving for profitable growth; pricey valuation

Sell: Vijaya Diagnostic Centre Ltd.

Recommendation

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q2FY24 result was a beat vs our estimates driven by 18.3% YoY growth in non-covid business. Test volume growth remained healthy at 18.7% YoY. In Q2, it commercialised a new hub in Kolkata; the company is witnessing good traction and expects the hub to breakeven in next three quarters.

Vijaya Diagnostic Centre Ltd. has lost -22.26% in the last 3 Months

Vijaya Diagnostic Centre Ltd.

11 Aug 2023

965.40

-0.57%

Growth trajectory unhurt

Accumulate: Vijaya Diagnostic Centre Ltd.

Recommendation Target

ICICI Securities Limited

Vijaya’s Q1FY24 performance beat our estimates driven by 19.2% YoY growth in non covid business. Test volume growth remained healthy at 17.5% YoY, aided by improvement in footfalls in the company’s mature and newer centres. Centres at Panjagutta and Rajamundhry have started gaining traction while Tirupati hub is expected to scale up in the coming quarters.

Vijaya Diagnostic Ce.. has an average target of 941.00 from 2 brokers.

Vijaya Diagnostic Centre Ltd.

31 May 2023

965.40

-0.57%

Non-covid patient footfall sturdy

Buy: Vijaya Diagnostic Centre Ltd.

Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q4FY23 performance was driven by a steady 22.4% YoY growth in non-covid business, while covid business’ contribution fell to 1% (15% in Q4FY22). Overheads of new centres impacted EBITDA margin to a small extent though, at 40.6% in Q4, it continues to be better than that of most of listed peers.

Vijaya Diagnostic Centre Ltd. has gained 41.38% in the last 1 Year

Vijaya Diagnostic Centre Ltd.

16 Feb 2023

965.40

-0.57%

Steady performance, healthy outlook

Buy: Vijaya Diagnostic Centre Ltd.

Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q3FY23 performance was broadly in line with our estimates. Revenues grew 2.1% YoY (-6.3% QoQ) to Rs1.1bn (I-Sec: Rs1.1bn). Covid revenues were negligible during the quarter. EBITDA margin declined 120bps QoQ to 39.1% (I-Sec: 38%) due to negative operating leverage.

Vijaya Diagnostic Ce.. has an average target of 941.00 from 2 brokers.

Vijaya Diagnostic Centre Ltd.

14 Nov 2022

965.40

-0.57%

Growth momentum to continue

Buy: Vijaya Diagnostic Centre Ltd.

Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q2FY23 performance was broadly in line with our estimates. Revenue grew 7.1% YoY and 15.7% QoQ to Rs1.2bn (I-Sec: Rs1.2bn).

Vijaya Diagnostic Centre Ltd. average weekly volume is high.

Vijaya Diagnostic Centre Ltd.

11 Aug 2022

965.40

-0.57%

Healthy recovery in non-covid business

Buy: Vijaya Diagnostic Centre Ltd.

Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q1FY23 performance was broadly in line with our estimates with revenue declining 14.9% YoY to Rs1.0bn (I-Sec: Rs1.0bn) on a high covid base.

Vijaya Diagnostic Centre Ltd. has gained 41.38% in the last 1 Year

Vijaya Diagnostic Centre Ltd.

05 Jan 2022

965.40

-0.57%

B2C-focused dominant Southern player

Buy: Vijaya Diagnostic Centre Ltd.

ICICI Securities Limited

Vijaya Diagnostic (Vijaya) is one of the largest integrated diagnostic chains in southern India and is primarily based in Andhra Pradesh and Telangana. Other factors that differentiate Vijaya from other diagnostic chains are: 1) ~92% of business is its B2C (provides stickiness) and 2) it offers a comprehensive basket of diagnostic services in both pathology and radiology

Vijaya Diagnostic Ce.. has an average target of 941.00 from 2 brokers.

Vijaya Diagnostic Centre Ltd.

01 Sep 2021

965.40

-0.57%

Vijaya Diagnostic Centre

IPO Note: Vijaya Diagnostic Centre Ltd.

Angel Broking

Vijaya Diagnostic Centre was incorporated in 2002, Company is the largest integrated diagnostic chain in southern India. Vijaya Diagnostic provides integrated services of pathology and radiology, company offers around 740 routine tests, 870 specialize pathology tests, 220 basic tests, and 320 advanced radiology tests. Vijaya diagnostic network consists of 80 diagnostic centers and 11 reference

Number of FII/FPI investors increased from 138 to 155 in Dec 2024 qtr.

VOTE: Is Vijaya Diagnostic Centre Ltd. worth buying?

37 Votes:

Buy 78.38%

Sell 13.51%

Hold 8.11%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf